-

Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day

OSLO, Norway--(BUSINESS WIRE)--Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.

Details are as follows:

  • Company panel discussion together with Point Biopharma, Fusion Pharmaceuticals, Aktis Oncology and Curie Therapeutics on Tuesday, May 17, 2022 at 1:30 p.m. ET.
  • Fireside chat with Charles Zhu, Vice President Guggenheim Securities LLC on Tuesday, May 17, 2022 at 4:30 p.m. ET.

About Oncoinvent

Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent’s lead candidate, Radspherin®, is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin® is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.

Contacts

Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com

IR enquiries:
Courtney Turiano, Stern Investor Relations
Email: Courtney.Turiano@sternir.com

Industry:

Oncoinvent

Release Versions
English

Contacts

Jan A. Alfheim, Chief Executive Officer
Cell: +47 46 44 00 45
Email: alfheim@oncoinvent.com

IR enquiries:
Courtney Turiano, Stern Investor Relations
Email: Courtney.Turiano@sternir.com

More News From Oncoinvent

Oncoinvent to Present at TD Cowen 45th Annual Health Care Conference

OSLO, Norway--(BUSINESS WIRE)--Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference being held from March 3-5, 2025 in Boston, MA. Details of the event are as follows: Date: Wednesday, March 5, 2025 Time: 10:30 a.m. ET The live audio webcast can be accessed here and on the News & Events section of Oncoinvent’s website at www.oncoinvent.com. A...

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities

OSLO, Norway--(BUSINESS WIRE)--Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has entered into an agreement with ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies. As part of the agreement, ARTBIO will rent space and equipment, acquire access to some of Oncoinvent’s radioprotection expertise and analytical services, and purchase select R&D eq...

Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatoses

OSLO, Norway--(BUSINESS WIRE)--Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced an interim data readout of the Phase 1/2a studies of Radspherin® for the treatment of peritoneal carcinomatoses. The studies were closed for recruitment at the end of 2023, and patients are currently in long-term follow-up. The readout confirmed the previously published results on efficacy and adds further confidence in the ongoing randomized...
Back to Newsroom